Le Lézard
Classified in: Health
Subject: MAT

NatureFine+ Releases New Retail Display for Their CBD Products

COMMACK, N.Y., July 16, 2020 /PRNewswire/ -- Naturefine+ was launched by East Coast manufacturing company The Emerald Corp in 2019. Consumers are buzzing about their interesting formulas that utilize a wide range of all-natural ingredients. Naturefine+ has disrupted the market with their aggressive price structure, eye-catching packaging and industry-leading compliance efforts. Their products are backed by layers of testing including; potency, heavy metal, pesticide, foreign matter, mold and residual solvents. Naturefine+ has now launched a new retail display for their CBD products. The sleek, acrylic display includes a sleeve (6 ct.) of each of their products. They offer a wide range of low MSRP ingestible and topical products for as low as $9.99. Their best-sellers include:

Naturefine+ can be found in over 2,500 retail locations and is planning to expand into an additional 10,000 stores in 2020. Coming off the launch of their new retail display, The Emerald Corp plans to create waves in the C-Store space by the end of this year. You can learn about Naturefine+ on their website.

*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.

Related Images


SOURCE NatureFine+

These press releases may also interest you

at 07:50
Vycellix, Inc., an immuno-centric discovery life science company with a focus on natural killer cell-based (NK cell) therapeutics, today announced that its Chairman & CEO, Evren Alici, M.D., Ph.D., will present at the upcoming Innate Killer Summit....

at 07:45
The "Oxygen Conservers (Anesthesia and Respiratory Devices) - Global Market Analysis and Forecast Model (COVID-19 market impact)" report has been added to ResearchAndMarkets.com's offering. This model is built to visualize quantitative market trends...

at 07:45
Biohaven Pharmaceutical Holding Company Ltd. , a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, today reported financial results for the...

at 07:35
Stoke Therapeutics, Inc. , a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today reported financial results for the second quarter of 2020 and provided...

at 07:35
Sesen Bio , a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported operating results for the second quarter ended June 30, 2020. The Company also provided an update on...

at 07:35
Navidea Biopharmaceuticals, Inc. ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce that it has signed a binding memorandum of understanding ("MOU")...

News published on 16 july 2020 at 10:00 and distributed by: